For Healthcare Providers
Clinic Dashboard
Real-time peptide intelligence for healthcare providers
13
Total Peptides
Scored & analyzed
379K
Monthly Searches
Global search volume
7
Protocol Stacks
Pre-built templates
8
Evidence Updates
Recent studies & alerts
Search Demand
Trending Peptides
Ranked by monthly search volume with year-over-year growth data.
| # | Peptide | Monthly Searches | YoY Growth | Kamura Score | Top Patient Question |
|---|---|---|---|---|---|
| 1 | BPC-157 | 165K | +89% | 85 | Is BPC-157 safe for long-term use? |
| 2 | GHK-Cu | 40K | +1,016% | 76 | Topical or injectable GHK-Cu — which is better? |
| 3 | CJC-1295 + Ipamorelin | 33K | +45% | 74 | How does CJC/Ipamorelin compare to HGH? |
| 4 | TB-500 | 27K | +62% | 71 | Can I stack TB-500 with BPC-157? |
| 5 | Semax | 22K | +78% | 58 | Does Semax actually improve focus? |
| 6 | Selank | 18K | +55% | 61 | Is Selank better than SSRIs for anxiety? |
| 7 | MOTS-c | 14K | +120% | 62 | Does MOTS-c really mimic exercise? |
| 8 | Epitalon | 12K | +95% | 55 | Can Epitalon reverse biological age? |
| 9 | Thymosin Alpha-1 | 11K | +40% | 77 | Is Thymosin Alpha-1 safe for autoimmune conditions? |
| 10 | AOD-9604 | 9K | +35% | 40 | How effective is AOD-9604 for belly fat? |
| 11 | KPV | 8K | +150% | 63 | Can KPV help with IBD/IBS? |
| 12 | SS-31 | 5K | +200% | 59 | Is SS-31 available in the UAE? |
| 13 | Tesamorelin | 15K | +30% | 73 | Is Tesamorelin only for HIV patients? |
Demand Breakdown
Search Volume by Goal
Aggregate monthly search volume for peptides in each goal category.
Latest Intelligence
Recent Evidence Updates
Studies, regulatory changes, and safety alerts.
FDA warns of contaminated research-grade peptides in grey market
FDA issued a safety alert after testing revealed that 23% of research-grade BPC-157 and TB-500 samples purchased online contained bacterial endotoxins exceeding safe limits. The agency emphasized the importance of pharmaceutical-grade sourcing.
Source: FDA Safety Communication
UAE MOHAP expands compounding pharmacy regulations for peptides
MOHAP issued updated guidance clarifying the legal pathway for physician-prescribed, pharmacy-compounded peptide therapy in the UAE. The new framework aligns with GMP standards and requires Certificate of Analysis documentation.
Source: MOHAP
FDA reclassifies 14 peptides back to Category 1
HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 restricted peptides will be reclassified back to Category 1, restoring the legal pathway for licensed compounding pharmacies. This is the biggest regulatory shift in peptide access in years.
Source: HHS Official Announcement